Hydroxytyrosol: a new class of microbicide displaying broad anti-HIV-1 activity

L. Bedoya, Manuela Beltrán, Patricia Obregón-Calderón, J. García-Pérez, Humberto E. de la Torre, Nuria González, M. Pérez-Olmeda, D. Auñón, L. Capa, E. Gómez-Acebo, J. Alcamí
{"title":"Hydroxytyrosol: a new class of microbicide displaying broad anti-HIV-1 activity","authors":"L. Bedoya, Manuela Beltrán, Patricia Obregón-Calderón, J. García-Pérez, Humberto E. de la Torre, Nuria González, M. Pérez-Olmeda, D. Auñón, L. Capa, E. Gómez-Acebo, J. Alcamí","doi":"10.1097/QAD.0000000000001283","DOIUrl":null,"url":null,"abstract":"Objective:To investigate the toxicity and activity against HIV of 5-hydroxytyrosol as a potential microbicide. Design:The anti-HIV-1 activity of 5-hydroxytyrosol, a polyphenolic compound, was tested against wild-type HIV-1 and viral clones resistant to nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors and integrase inhibitors. In addition to its activity against founder viruses, different viral subtypes and potential synergy with tenofovir disoproxil fumarate, lamivudine and emtricitabine was also tested. 5-Hydroxytyrosol toxicity was evaluated in vivo in rabbit vaginal mucosa. Methods:We have cloned pol gene from drug-resistant HIV-1 isolated from infected patients and env gene from Fiebeg III/IV patients or A, C, D, E, F and G subtypes in the NL4.3-Ren backbone. 5-Hydroxytyrosol anti-HIV-1 activity was evaluated in infections of MT-2, U87-CCR5 or peripheral blood mononuclear cells preactivated with phytohemagglutinin + interleukin-2 with viruses obtained through 293T transfections. Inhibitory concentration 50% and cytotoxic concentration 50% were calculated. Synergy was analysed according to Chou and Talalay method. In-vivo toxicity was evaluated for 14 days in rabbit vaginal mucosa. Results:5-Hydroxytyrosol inhibited HIV-1 infections of recombinant or wild-type viruses in all the target cells tested. Moreover, 5-hydroxytyrosol showed similar inhibitory concentration 50% values for infections with NRTIs, NNRTIs, protease inhibitors and INIs resistant viruses; founder viruses and all the subtypes tested. Combination of 5-hydroxytyrosol with tenofovir was found to be synergistic, whereas it was additive with lamivudine and emtricitabine. In-vivo toxicity of 5-hydroxytyrosol was very low even at the highest tested doses. Conclusion:5-Hydroxytyrosol displayed a broad anti-HIV-1 activity in different cells systems in the absent of in-vivo toxicity, therefore supporting its candidacy as a potential new class of microbicides.","PeriodicalId":355297,"journal":{"name":"AIDS (London, England)","volume":"65 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2016-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"21","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"AIDS (London, England)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/QAD.0000000000001283","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 21

Abstract

Objective:To investigate the toxicity and activity against HIV of 5-hydroxytyrosol as a potential microbicide. Design:The anti-HIV-1 activity of 5-hydroxytyrosol, a polyphenolic compound, was tested against wild-type HIV-1 and viral clones resistant to nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors and integrase inhibitors. In addition to its activity against founder viruses, different viral subtypes and potential synergy with tenofovir disoproxil fumarate, lamivudine and emtricitabine was also tested. 5-Hydroxytyrosol toxicity was evaluated in vivo in rabbit vaginal mucosa. Methods:We have cloned pol gene from drug-resistant HIV-1 isolated from infected patients and env gene from Fiebeg III/IV patients or A, C, D, E, F and G subtypes in the NL4.3-Ren backbone. 5-Hydroxytyrosol anti-HIV-1 activity was evaluated in infections of MT-2, U87-CCR5 or peripheral blood mononuclear cells preactivated with phytohemagglutinin + interleukin-2 with viruses obtained through 293T transfections. Inhibitory concentration 50% and cytotoxic concentration 50% were calculated. Synergy was analysed according to Chou and Talalay method. In-vivo toxicity was evaluated for 14 days in rabbit vaginal mucosa. Results:5-Hydroxytyrosol inhibited HIV-1 infections of recombinant or wild-type viruses in all the target cells tested. Moreover, 5-hydroxytyrosol showed similar inhibitory concentration 50% values for infections with NRTIs, NNRTIs, protease inhibitors and INIs resistant viruses; founder viruses and all the subtypes tested. Combination of 5-hydroxytyrosol with tenofovir was found to be synergistic, whereas it was additive with lamivudine and emtricitabine. In-vivo toxicity of 5-hydroxytyrosol was very low even at the highest tested doses. Conclusion:5-Hydroxytyrosol displayed a broad anti-HIV-1 activity in different cells systems in the absent of in-vivo toxicity, therefore supporting its candidacy as a potential new class of microbicides.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
羟基酪醇:一类具有广泛抗hiv -1活性的新型杀微生物剂
目的:研究5-羟基酪醇作为一种潜在的杀菌剂的毒性和抗HIV活性。设计:研究了5-羟基酪醇(一种多酚类化合物)对核苷类逆转录酶抑制剂(NRTIs)、非核苷类逆转录酶抑制剂(NNRTIs)、蛋白酶抑制剂和整合酶抑制剂耐药的野生型HIV-1和病毒克隆的抗HIV-1活性。除了对方正病毒的活性外,还测试了不同病毒亚型及其与富马酸替诺福韦、拉米夫定和恩曲他滨的潜在协同作用。研究了5-羟基酪醇对兔阴道粘膜的体内毒性。方法:从感染患者分离的耐药HIV-1中克隆pol基因,从Fiebeg III/IV患者或NL4.3-Ren主干的A、C、D、E、F和G亚型中克隆env基因。用293T转染获得的病毒感染MT-2、U87-CCR5或植物血凝素+白细胞介素-2预激活的外周血单个核细胞,评估5-羟基酪醇抗hiv -1的活性。计算抑制浓度50%和细胞毒浓度50%。根据Chou和Talalay方法对协同效应进行了分析。在兔阴道粘膜中观察14天的体内毒性。结果:5-羟基酪醇在所有靶细胞中均能抑制重组或野生型HIV-1病毒的感染。此外,5-羟基酪醇对NRTIs、NNRTIs、蛋白酶抑制剂和INIs耐药病毒感染的抑制浓度50%值相似;方正病毒和所有测试过的亚型。5-羟基酪醇与替诺福韦的联合被发现是协同的,而它与拉米夫定和恩曲他滨是加法。5-羟基酪醇的体内毒性即使在最高试验剂量下也很低。结论:5-羟基酪醇在不同细胞系统中表现出广泛的抗hiv -1活性,且无体内毒性,因此支持其作为潜在的新型杀微生物剂的候选。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Primary HIV infection during chronic treatment with imatinib: impact on infection dynamics Coronavirus disease 2019 outcomes in a population-based cohort of people with HIV and a matched cohort of people without HIV during Omicron variant waves Vespers: A nursing origin story set in the dawn of the HIV pandemic Presence of the M184I mutation after short-term exposure to azvudine for COVID-19 in people living with HIV Glottic Kaposi's sarcoma
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1